Literature DB >> 18089624

Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.

Sascha David1, Philipp Kümpers, Vega Seidler, Frank Biertz, Hermann Haller, Danilo Fliser.   

Abstract

BACKGROUND: Natriuretic peptides such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) have become increasingly important in diagnosing left ventricular dysfunction (LVD), however, in patients with chronic kidney disease (CKD), their use is confounded by concomitant volume overload and reduced renal excretion. We hypothesized that a serum NT-proBNP cut-off value adjusted for patients with CKD could serve as a biochemical marker to detect LVD in patients on haemodialysis treatment regardless of chronic fluid overload.
METHODS: We assessed LV function using trans-thoracic echocardiography and indices of hydration status such as extracellular water (ECW) using bioelectrical impedance analysis (BIA) in 62 stable patients on maintenance haemodialysis. NT-proBNP cutoff values for LVD with different specificities and sensitivities were calculated by ROC curves.
RESULTS: We found a significant inverse correlation between LV ejection fraction (EF) and NT-proBNP levels (r = -0.77, P < 0.0001). In the multivariate regression analysis NT-proBNP was the only independent predictor of EF (r = 0.699, P < 0.0001). NT-proBNP levels were significantly higher (P < 0.0001) in patients with LVD (n = 15; 32 760 +/- 6605 ng/L) compared to those without LVD (n = 47; 2835 +/- 428 ng/L). An NT-proBNP cut-off value of 7168 ng/L resulted in 90% specificity and 79% sensitivity for the presence of LVD, i.e. an EF <45% (AUC(ROC): 0.95 +/- 0.03, P < 0.0001). Furthermore, in patients with LVD we found a significant relationship between serum NT-proBNP and markers of fluid overload such as the ECW/body weight ratio (P < 0.0001) and the grade of peripheral oedema (P = 0.007), but not in patients without LVD.
CONCLUSION: A serum NT-proBNP cut-off value of >/=7200 ng/L discriminates CKD stage 5 patients without LVD from those with LVD. In those patients with LVD, persistent post-dialytic volume overload correlates with elevated NT-proBNP levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089624     DOI: 10.1093/ndt/gfm700

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  25 in total

1.  N-terminal proBNP--marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients?

Authors:  John Booth; Jennifer Pinney; Andrew Davenport
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

2.  Dry weight assessment by combined ultrasound and bioimpedance monitoring in low cardiovascular risk hemodialysis patients: a randomized controlled trial.

Authors:  Dimitrie Siriopol; Mihai Onofriescu; Luminita Voroneanu; Mugurel Apetrii; Ionut Nistor; Simona Hogas; Mehmet Kanbay; Radu Sascau; Dragos Scripcariu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-12-07       Impact factor: 2.370

Review 3.  The relationship of volume overload and its control to hypertension in hemodialysis patients.

Authors:  Jennifer E Flythe; Nisha Bansal
Journal:  Semin Dial       Date:  2019-09-29       Impact factor: 3.455

4.  Relation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and left atrial volume index to left ventricular function in chronic hemodialysis patients.

Authors:  Mayuko Yamazaki; Tetsuya Ogawa; Noriko Tamei; Yoshitaka Ando; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

5.  Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study.

Authors:  Meyeon Park; Eric Vittinghoff; Michael G Shlipak; Rakesh Mishra; Mary Whooley; Nisha Bansal
Journal:  Am Heart J       Date:  2014-10-14       Impact factor: 4.749

6.  N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients.

Authors:  Magid A Fahim; Andrew Hayen; Andrea R Horvath; Goce Dimeski; Amanda Coburn; David W Johnson; Carmel M Hawley; Scott B Campbell; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-24       Impact factor: 8.237

Review 7.  Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?

Authors:  Thanat Chaikijurajai; Hernan Rincon Choles; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2020-09-17

8.  B-type natriuretic peptide is not a volume marker among patients on hemodialysis.

Authors:  Rajiv Agarwal
Journal:  Nephrol Dial Transplant       Date:  2013-03-22       Impact factor: 5.992

9.  Biomarkers in predicting mortality and treatment in hemodialysis patients.

Authors:  Angela Yee-Moon Wang
Journal:  F1000 Med Rep       Date:  2009-03-17

10.  Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease.

Authors:  B Tirmenstajn-Jankovic; N Dimkovic; G Perunicic-Pekovic; Z Radojicic; D Bastac; S Zikic; M Zivanovic
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.